Medicare Expands GLP-1 Weight-Loss Drug Coverage Starting Now
Medicare has begun covering GLP-1 drugs for obesity, a shift that could benefit millions of enrollees previously denied access.
A significant coverage expansion quietly took effect this week, opening the door for millions of Medicare beneficiaries to access GLP-1 medications — the blockbuster class of drugs that includes Ozempic and Wegovy — specifically for weight-loss treatment. Until now, the program had drawn a firm line, covering these drugs only when prescribed for Type 2 diabetes, sleep apnea, or elevated cardiovascular risk such as prior stroke or heart attack.
The policy shift represents a meaningful departure from Medicare's historically restrictive posture toward obesity pharmacotherapy. For decades, the program treated obesity largely as a lifestyle issue rather than a clinical condition warranting pharmaceutical intervention, leaving beneficiaries to shoulder out-of-pocket costs that can run into hundreds or even thousands of dollars per month at retail prices.
Read more Witkoff and Kushner Head to Qatar With No Iran Talks Scheduled →
The practical implications for enrollees are substantial. Seniors and qualifying disabled Americans who have struggled to obtain coverage for GLP-1s — drugs that clinical trials have shown can reduce body weight by 15% or more — may now find a path through Medicare's pharmacy benefit, though plan-specific formularies, prior authorization requirements, and cost-sharing structures will shape what individuals actually pay.
The expansion also arrives at a moment of intense fiscal scrutiny. GLP-1 drugs are among the most expensive therapies in widespread use, and any large-scale uptake among Medicare's more than 65 million enrollees could carry significant budgetary weight. Policymakers and health economists will be watching utilization data closely to understand the downstream cost-benefit calculus, including potential savings from reduced obesity-related complications.
For beneficiaries eager to explore their options, understanding their specific plan's formulary and any step-therapy requirements will be essential first steps. Continue reading at MarketWatch.com
